NU 2002-081, NU 2003-053 and NU 2004-095

Inventors

Thomas Adrian

Wenxin Gu

Shouxin Liu

Richard Silverman*

Gerald Soff

Short Description

Synthesis of a novel family of peptide compounds with increased anti-proliferative activity

Abstract

Northwestern researchers have synthesized novel peptides based upon natural marine products that exhibit cytotoxicity against a variety of cancer cells lines. Sansalvamide A and Scytalidamide A are two such natural products. The inventors created cyclic peptide analogs that display greater anticancer activity compared to these known growth inhibitors. Importantly, the analogs also exhibit an 80-fold reduction in effective dosage with greater efficacy. The scientists have developed an efficient solid phase synthesis of the cyclic peptides, creating a series of compounds that have already been successfully tested in vitro across several human cancer cells lines, including prostate cancer, breast cancer, melanoma, and colon cancers.

Applications

• Therapeutics: Anti-Cancer

Advantages

• Enhanced anti-proliferative activity
• Improved dosage efficacy
• Efficient solid phase synthesis of compounds
• Effective against a variety of cancer cell lines

Publications

Liu S, Gu W, Lo D, Ding X, Ujiki M, Adrian T, Soff G, Silverman R (2005) N-methylsansalvamide a peptide analogues. Potent new antitumor agents. Journal of Medicinal Chemistry. 48:3630-38.

Ujiki M, Milam B, Ding X, Roginsky A, Salabat M, Talamonti M, Bell R, Gu W, Silverman R, Adrian T (2006) A novel peptide sansalvamide analogue inhibits pancreatic cancer cell growth through G0/G1 cell-cycle arrest. Biochemical & Biophysical Research Communications 340: 1224-1228.

IP Status

Issued US Patent No. 7,709,443